

REMARKS

In the present claim amendments, Claims 6, 8, 15, 18, 40, 42, 46, 59-61, and 73-79 have been canceled without prejudice. Claims 21-23, 48, 62-63, 66-68, and 71 were canceled in the previous preliminary amendment.

Claims 1-5, 7, 9-14, 20, 24, and 25 have been amended to recite a “composition” instead of a “compound.” This was simply done to avoid confusion with the recited “chromium compound” of claim 25 *et seq.* Support for these amendments can be found in original claims 73-79. Claim 1 has been amended to recite the formula of original claim 6. Claim 14 has been amended to correct a clerical error by deleting the term “compound” and inserting the term “atom” therefore. Claim 16 has been rewritten as an independent claim. Claim 19 has been amended to depend on claim 16. Claim 25 has been amended to recite the formula of original claim 40. Claim 41 has been amended to depend on claim 25. Claims 47, 52, 64, 65, 69, and 72 have been amended to recite the unsaturated fatty acid residue of claim 1.

No new matter has been added by these amendments.

Applicant awaits an action on the merits.

No additional claim fees are believed to be due; however, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account No. 14-0629.

Respectfully submitted,

BALLARD SPAHR ANDREWS &
INGERSOL, LLP

/Christopher L. Curfman/

Christopher L. Curfman, JD, PhD
Registration No. 52,787

BALLARD SPAHR ANDREWS & INGERSOL, LLP
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

CERTIFICATE OF EFS-WEB TRANSMISSION UNDER 37 CFR § 1.8

I hereby certify that this Response, including any items indicated as attached or enclosed, is being transmitted by EFS-WEB on the date indicated below.

/Christopher L. Curfman/

August 28, 2008

Christopher L. Curfman

Date